Optic neuritis in various demyelinating diseases ; Оптические невриты при различных демиелинизирующих заболеваниях

Συγγραφείς: A. K. Kalashnikova, D. D. Eliseeva, N. A. Andreeva, N. V. Zhorzholadze, I. A. Ronzina, R. Ts. Bembeeva, N. N. Venediktova, M. R. Kalganova, N. L. Sheremet, А. К. Калашникова, Д. Д. Елисеева, Н. А. Андреева, Н. В. Жоржоладзе, И. А. Ронзина, Р. Ц. Бембеева, Н. Н. Венедиктова, М. Р. Калганова, Н. Л. Шеремет

Πηγή: Neurology, Neuropsychiatry, Psychosomatics; Vol 16, No 3 (2024); 52-57 ; Неврология, нейропсихиатрия, психосоматика; Vol 16, No 3 (2024); 52-57 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2024-3

Θεματικοί όροι: оптическая когерентная томография, neuromyelitis optica spectrum disorders, a disease associated with the presence of antibodies against myelin oligodendrocyte glycoproteins, multiple sclerosis, demyelinating diseases, optical coherence tomography, заболевание спектра оптиконевромиелита, расстройство, ассоциированное с наличием антител к миелиновым олигодендроцитарным гликопротеинам, рассеянный склероз, демиелинизирующие заболевания

Περιγραφή αρχείου: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/2287/1674; https://nnp.ima-press.net/nnp/article/view/2287/1680; Petzold A, Fraser CL, Abegg M, et al. Diagnosis and classification of optic neuritis. Lancet Neurol. 2022 Dec;21(12):1120-34. doi:10.1016/S1474-4422(22)00200-9. Epub 2022 Sep 27.; Sarkar P, Mehtani A, Gandhi HC, et al. Atypical optic neuritis: An overview. Indian J Ophthalmol. 2021 Jan;69(1):27-35. doi:10.4103/ijo.IJO_451_20; Zhang Y, Qiu W, Guan H, et al. Antibody-Mediated Autoimmune Diseases of the CNS: Challenges and Approaches to Diagnosis and Management. Front Neurol. 2022 Mar 2;13:844155. doi:10.3389/fneur.2022.844155; Шерман МА, Бойко АН. Эпидемиология заболеваний спектра оптиконейромиелита. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2021;121(7-2):5-12. doi:10.17116/jnevro20211210725; Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol. 2023 Mar;22(3):268-82. doi:10.1016/S1474-4422(22)00431-8. Epub 2023 Jan 24.; Cacciaguerra L, Flanagan EP. Updates in NMOSD and MOGAD Diagnosis and Treatment: A Tale of Two Central Nervous System Autoimmune Inflammatory Disorders. Neurol Clin. 2024 Feb;42(1):77-114. doi:10.1016/j.ncl.2023.06.009. Epub 2023 Aug 7.; Gaier ED, Boudreault K, Rizzo JF 3rd, et al. Atypical Optic Neuritis. Curr Neurol Neurosci Rep. 2015 Dec;15(12):76. doi:10.1007/s11910-015-0598-1; Lin TY, Chien C, Lu A, et al. Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. Expert Rev Neurother. 2021 Oct;21(10):1101-23. doi:10.1080/14737175.2021.1982697. Epub 2021 Oct 11.; Chen JJ, Sotirchos ES, Henderson AD, et al. OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG anti body-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS. Mult Scler Relat Disord. 2022 Feb;58:103525. doi:10.1016/j.msard.2022.103525. Epub 2022 Jan 11.; Patil SA, Grossman S, Kenney R, et al. Where's the Vision? The Importance of Visual Outcomes in Neurologic Disorders: The 2021 H. Houston Merritt Lecture. Neurology. 2023 Jan 31;100(5):244-53. doi:10.1212/WNL.0000000000201490. Epub 2022 Dec 15.; Jarius S, Aktas O, Ayzenberg I, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) — revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. 2023 Jul;270(7):3341-68. doi:10.1007/s00415-023-11634-0. Epub 2023 Apr 6.; Dhar N, Kumar M, Tiwari A, et al. Comparison of clinico-radiological profile, optical coherence tomography parameters, and outcome in MOGAD and Neuromyelitis optica spectrum disorder subtypes: A prospective observational study. J Neurosci Rural Pract. 2023 Apr-Jun;14(2):239-51. doi:10.25259/JNRP_8_2022. Epub 2023 Feb 23.; Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017 Apr 1;389(10076):1336-46. doi:10.1016/S0140-6736(16)30959-X. Epub 2016 Nov 24.; Wingerchuk DM, Banwell B, Bennett JL, et al; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi:10.1212/WNL.0000000000001729. Epub 2015 Jun 19.; Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. J Neuroinflammation. 2018 May 3;15(1):134. doi:10.1186/s12974-018-1144-2; Ramanathan S, Reddel SW, Henderson A, et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40. doi:10.1212/NXI.0000000000000040; Kümpfel T, Giglhuber K, Aktas O, et al; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) — revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024 Jan;271(1):141-76. doi:10.1007/s00415-023-11910-z. Epub 2023 Sep 7. Erratum in: J Neurol. 2024 Apr 5.; Outteryck O, Majed B, Defoort-Dhellemmes S, et al. A comparative optical coherence tomography study in neuromyelitis optica spectrum disorder and multiple sclerosis. Mult Scler. 2015 Dec;21(14):1781-93. doi:10.1177/1352458515578888. Epub 2015 Mar 31.; Oertel FC, Sotirchos ES, Zimmermann HG, et al; with the GJCF International Clinical Consortium for NMOSD and the CROCTINO study group. Longitudinal Retinal Changes in MOGAD. Ann Neurol. 2022 Sep;92(3):476-85. doi:10.1002/ana.26440. Epub 2022 Jul 16.

Διαθεσιμότητα: https://nnp.ima-press.net/nnp/article/view/2287
https://doi.org/10.14412/2074-2711-2024-3-52-57

СОЦИАЛЬНО – ЭКОНОМИЧЕСКОЕ БРЕМЯ ЗАТРАТ ГОСУДАРСТВА ПРИ БОЛЕЗНИ СПЕКТРА ОПТИКОНЕВРОМИЕЛИТА В РОССИЙСКОЙ ФЕДЕРАЦИИ

Θεματικοί όροι: заболевание спектра оптиконевромиелита, косвенные издержки, opticoneuromyelitis spectrum disease, socio–economic burden (SEB), direct medical costs, ЗСОНМ, прямые медицинские затраты, влияние на бюджет, SDONM, impact on the budget, 3. Good health, direct non-medical costs, прямые не медицинские затраты, indirect costs, социально – экономическое бремя (СЭБ)